Advancing Liver Cell Therapies with Likarda’s Hydrogel Encapsulation

We’re excited to share our latest peer-reviewed publication highlighting how Likarda’s Core-Shell Spherification™ (CSS) technology is overcoming a major challenge in liver cell-based therapies.

🔬 Key Findings:
✔ Extended hepatocyte viability in vivo without triggering an immune response
✔ Improved metabolic activity and function compared to traditional encapsulation methods
✔ Potential for broader applications, including islet cell therapies for type 1 diabetes

💡 Why It Matters:
Liver disease remains a major unmet medical need, with cell-based therapies facing immune rejection and short-lived efficacy. Our PVA-based hydrogel encapsulation shows strong potential to improve long-term success, offering hope for new cell therapy treatments.